摘要:
A method for modifying at least one non-ester-containing parent compound, and the compounds produced using such method, which compounds are deployed to temporarily incapacitate at least one subject are disclosed. The modified compounds are rapidly metabolized to inactive and non-toxic metabolites when exposure to the modified compounds is halted. One or more of a predetermined chemical arrangement is incorporated into the parent compound having the formula (I): Phi-R-X-R'; where Phi is a phenyl, substituted aryl or heteroaryl system present in the parent compound or is 10 added to the parent compound; R is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons present in the parent compound or is added to Phi; X is a carboxyl, sulfoxyl or phosphatyl function added to R; and, R' is an alkyl, alkenyl or aralkyl group either branched or unbranched containing from 1 to 10 carbons is added to X in a metabolically 15 labile manner, or is a structural element already present as an inherent portion of the parent compound that is connected to X in a metabolically labile manner.
摘要:
Compounds which are the reaction product of allicin and ACE-inhibiting compounds are useful in treating hypertension, elevated triglycerides, and elevated insulin.
摘要:
Substituted heterocyclic compounds are disclosed. The compounds are useful for treating multidrug resistance. The compounds can be formulated in compositions with a carrier and, optionally, a therapeutic agent. One suitable substituted heterocyclic compound has formula (I).
摘要:
Novel hydroxamic acid derivatives, e.g., of formula (I), wherein R1, R2, R3 and R4 are as defined, are found to be useful as pharmaceuticals, e.g., for the suppression of TNF release and the treatment of autoimmune and inflammatory diseases, e.g., multiple sclerosis and rheumatoid arthritis. Methods of making the compounds, novel intermediates, and pharmaceutical compositions comprising the compounds are provided.
摘要:
The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
摘要:
The present invention provides compounds of Formula (I), wherein A, B, C, G, and W have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful to treat thrombotic disorders. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (I), processes for preparing compounds of Formula (I), and intermediates useful for preparing compounds of Formula (I).
摘要:
The present invention discloses novel substituted aryl alkylamine compounds of Formula (I) or pharmaceutically acceptable salts thereofwhich have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such cyclic amines as well as methods of using them to treat obesity and other histamine H3 receptor -related diseases.
摘要:
The present invention relates generally to methods for treating or preventing nerve injury in a warm-blooded animal caused as a consequence of surgery by administering neurotrophic compounds described below. The invention relates more specifically to methods for treating or preventing nerve injury caused as a consequence of prostate surgery as well as erectile dysfunction.
摘要:
The present invention relates to novel compounds of formula (I): , their use for inhibiting serine proteases, such as dipeptidyl peptidases, such as dipeptidyl peptidase IV (DPP-IV) and to methods for their production and their therapeutic utility.
摘要:
The present invention relates to novel compounds of formula (I):, their use for inhibiting serine proteases, such as dipeptidyl peptidases, such as dipeptidyl peptidase IV (DPP-IV) and to methods for their production and their therapeutic utility.